Chukyoiyakuhin
4558.TTSE STANDARDPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥6.6bn | ¥6.3bn | ¥6.1bn | ¥5.7bn | ¥5.4bn | ¥5.8bn |
| Operating income | ¥127m | ¥106m | ¥128m | ¥60m | ¥64m | ¥226m |
| Ordinary income | ¥140m | ¥117m | ¥148m | ¥80m | ¥84m | ¥238m |
| Total assets | ¥5.3bn | ¥5.1bn | ¥5.1bn | ¥5.2bn | ¥5.3bn | ¥5.2bn |
| Net assets / equity | ¥2.6bn | ¥2.5bn | ¥2.5bn | ¥2.6bn | ¥2.6bn | ¥2.4bn |
| Operating cash flow | ¥99m | ¥32m | ¥172m | ¥106m | −¥223m | ¥344m |
| EPS (basic) | ¥7.84 | ¥4.24 | ¥-2.57 | ¥1.36 | ¥3.16 | ¥10.51 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 119 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 73 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 120 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 73 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 120 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 51 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 75 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 120 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 53 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 77 figures · EDINET |
| 2021-04-01 → 2022-03-31 | AnnualAmended | 122 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 49 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 122 figures · EDINET |
34 more reports are still being processed.